Dec 19, 2024 8:00 am EST Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Dec 3, 2024 8:00 am EST Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
Nov 12, 2024 8:00 am EST Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update
Sep 30, 2024 8:00 am EDT Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Sep 5, 2024 8:43 pm EDT UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Sep 5, 2024 8:00 am EDT Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Aug 20, 2024 8:00 am EDT Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
Aug 13, 2024 8:00 am EDT Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update